Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027)

被引：0
|
作者：
Lai, Ching-Lung
Chang, Ting-Tsung
Chao, You-Chen
Tanwandee, Tawesak
Thongsawat, Satawat
Lee, Shou-Dong
Angus, Peter
Zink, Richard
Zhu, Jin
Brett-Smith, Helena
Neo, Boon-Leong
机构：
[1] Queen Mary Hosp, Hong Kong 70101, Peoples R China
[2] Natl Cheng Kung Univ, Coll Med, Tainan, Taiwan
[3] Tri Serv Gen Hosp, Taipei 10700, Taiwan
[4] Mahidol Univ, Siriraj Hosp, Bangkok, Thailand
[5] Maharajnakorn Chiang Mai Hosp, Chiang Mai, Thailand
[6] Taipei Vet Gen Hosp, Taipei, Taiwan
[7] Austin & Repatriation Med Ctr, West Heidelbrg, Vic, Australia
[8] Bristol Myers Squibb Pharmaceut Res Inst, Wallingford, CT USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A128 / A128
页数：1
相关论文
共 50 条
  • [41] Tenofovir is superior to entecavir in HBeAg positive treatment Naive chronic hepatitis B Patients
    Behera, Manas Kumar
    Pati, Girish Kumar
    Singh, Ayaskant
    Narayan, Jimmy
    Sahu, Manoj Kumar
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 474 - 474
  • [42] Durability of HBeAg Seroconversion After Treatment with Entecavir or Tenofovir in Chronic Hepatitis B Patients
    Fong, Tse-Ling
    Mena, Edward A.
    Yu, Andy S.
    Quang-Quoc Phan
    Han, Steven-Huy B.
    Tien, Andy
    Velasco, Andrew J.
    Leduc, Vinh-Huy
    Tong, Myron J.
    HEPATOLOGY, 2014, 60 : 1121A - 1122A
  • [43] VIROLOGICAL RESPONSE AT 12 WEEKS OF ENTECAVIR THERAPY PREDICTS HBeAg CLEARANCE IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS
    Song, B. -C
    Chae, H. B.
    Kim, Y. N.
    Lee, B. S.
    Cho, Y. -K
    JOURNAL OF HEPATOLOGY, 2009, 50 : S237 - S237
  • [44] NO RESISTANCE TO TENOFOVIR ALAFENAMIDE DETECTED THROUGH 96 WEEKS OF TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS B
    Chan, Henry Lik-Yeun
    Marcellin, Patrick
    Cathcart, Andrew L.
    Bhardwaj, Neeru
    Flaherty, John F.
    Gaggar, Anuj
    Izumi, Namiki
    Lim, Young-Suk
    GUT, 2018, 67 : A96 - A97
  • [45] No Resistance to Tenofovir Alafenamide Detected Through 96 Weeks of Treatment in Patients with Chronic Hepatitis B
    Chan, Henry Lik-Yuen
    Marcellin, Patrick
    Pan, Calvin Q.
    Cathcart, Andrea L.
    Bhardwaj, Neeru
    Liu, Yang
    Cox, Stephanie
    Parhy, Bandita
    Zhou, Eric
    Flaherty, John F.
    Miller, Michael D.
    Gaggar, Anuj
    Shalimar
    Izumi, Namiki
    Lim, Young-Suk
    HEPATOLOGY, 2017, 66 : 11A - 11A
  • [46] Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naive Chinese patients with chronic hepatitis B: a randomized, multicenter study
    Yao, Guangbi
    Chen, ChengWei
    Lu, WeiLun
    Ren, Hong
    Tan, DeMing
    Wang, YuMing
    Xu, DaoZheng
    Liu, Jessica
    Xu, Dong
    Llamoso, Cyril
    HEPATOLOGY INTERNATIONAL, 2008, 2 (04) : 486 - 493
  • [47] HBeAg seroconversion is lower in Asian versus non-Asian patients during treatment of chronic hepatitis B with tenofovir (TDF) or entecavir (ETV)
    Jo, Kahee
    Dodge, Jennifer L.
    Wadley, Adrian
    Wakil, Adil E.
    Baron, Jody L.
    Cooper, Stewart
    HEPATOLOGY, 2013, 58 : 669A - 670A
  • [48] Virologic, serologic and biochemical outcomes through 3 years of entecavir treatment in nucleos(t)ide-naive Chinese chronic hepatitis B patients
    Yao, G. B.
    Ren, H.
    Xu, D. Z.
    Zhou, X. Q.
    Jia, J. D.
    Wang, Y. M.
    Chen, C. W.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A177 - A177
  • [49] Entecavir maleate versus Entecavir in Chinese patients with HBeAg-Positive Chronic Hepatitis B: Results at 48 and 96 weeks of a Randomized Double-blind Multicenter Clinical Trial
    Yu, Yanyan
    Xu, Jinghang
    Tang, Hong
    Zhang, Dazhi
    Mao, Qing
    Li, Jun
    Xu, Zhongnan
    Zhang, Xiquan
    Dai, Jun
    Si, Chongwen
    HEPATOLOGY, 2012, 56 : 397A - 398A
  • [50] Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study
    Guangbi Yao
    ChengWei Chen
    WeiLun Lu
    Hong Ren
    DeMing Tan
    YuMing Wang
    DaoZheng Xu
    Jessica Liu
    Dong Xu
    Cyril Llamoso
    Hepatology International, 2008, 2 : 486 - 493
12345